Important Instructions for 2019 N-SSATS

Located on the back of this instructions page is a worksheet consisting of questions 31 through 36 from the 2019 N-SSATS. These questions contain several important components of information that will be collected during your completion of the client counts section of the survey. To preview the client counts section for wording and specifics of who to count, please visit https://info.nssats.com and click on the questionnaire.

In addition to the client counts that have been collected in previous years (inpatient, residential, outpatient, methadone, buprenorphine, and naltrexone), this year we are also asking for numbers of clients receiving specific medications for alcohol use disorder.

To save time, and to complete the survey more efficiently on the Internet, you may wish to gather this information prior to beginning the survey. If you do collect this information ahead of time, please be sure to keep this sheet accessible for when you complete the questionnaire online. Although this is not a necessary step to completing the questionnaire, it may ease your survey completion process. Please keep the following points in mind when completing this worksheet.

- **Questions 31 through 36** on the N-SSATS ask about the number of clients in treatment on or as of March 29, 2019. If possible, report clients for this facility only.

- If you have multiple facilities in your network/organization, please write your “Facility/Group name” in the space provided at the top of the worksheet on the back of these instructions to keep track of each of your facility’s client counts. It might be helpful to make a copy of the worksheet for each facility/group.

- You may use estimated information to indicate your client counts, if necessary.

- Please refer to the enclosed pink flyer in your survey packet to obtain your facility’s web survey login information.

- Please transfer all of the information from your client counts worksheet into the client counts section of the web survey.
### 2019 National Survey of Substance Abuse Treatment Services (N-SSATS)
#### Client Counts Worksheet

**Facility/Group name:** ____________________________________________

### HOSPITAL INPATIENT CLIENT COUNTS
**SKIP THIS SECTION IF NO HOSPITAL INPATIENTS**

**Hospital Inpatients on March 29, 2019**

- _____ Inpatient detoxification
- _____ Inpatient treatment
- _____ Total Inpatients (Sum of categories above)
- _____ Total inpatients under age 18

**Patients Receiving Medications for Detoxification, Maintenance, or Relapse Prevention for Opioid Use Disorder**

- _____ Dispensed Methadone
- _____ Dispensed or prescribed Buprenorphine
- _____ Administered Naltrexone

**Patients Receiving Medications for Alcohol Use Disorder**

- _____ Dispensed or prescribed Disulfiram (Antabuse®)
- _____ Dispensed or prescribed Naltrexone
- _____ Dispensed or prescribed Acamprosate (Campral®)

**Inpatient Beds**

- _____ Inpatient beds specifically designated for substance use treatment

### OUTPATIENT CLIENT COUNTS
**SKIP THIS SECTION IF NO OUTPATIENT CLIENTS**

**Active Outpatients as of March 29, 2019**

- _____ Outpatient detoxification
- _____ Outpatient methadone/buprenorphine maintenance or naltrexone treatment
- _____ Outpatient day treatment or partial hospitalization
- _____ Intensive outpatient treatment
- _____ Regular outpatient treatment
- _____ Total Outpatient Clients (Sum of categories above)
- _____ Total outpatient clients under age 18

**Clients Receiving Medications for Detoxification, Maintenance, or Relapse Prevention for Opioid Use Disorder**

- _____ Dispensed Methadone
- _____ Dispensed or prescribed Buprenorphine
- _____ Administered Naltrexone

**Clients Receiving Medications for Alcohol Use Disorder**

- _____ Dispensed or prescribed Disulfiram (Antabuse®)
- _____ Dispensed or prescribed Naltrexone
- _____ Dispensed or prescribed Acamprosate (Campral®)

### RESIDENTIAL (NON-HOSPITAL) CLIENT COUNTS
**SKIP THIS SECTION IF NO RESIDENTIAL CLIENTS**

**Residential Clients on March 29, 2019**

- _____ Residential detoxification
- _____ Residential short-term treatment
- _____ Residential long-term treatment
- _____ Total Residential Clients (Sum of categories above)
- _____ Total residential clients under age 18

**Clients Receiving Medications for Detoxification, Maintenance, or Relapse Prevention for Opioid Use Disorder**

- _____ Dispensed Methadone
- _____ Dispensed or prescribed Buprenorphine
- _____ Administered Naltrexone

**Clients Receiving Medications for Alcohol Use Disorder**

- _____ Dispensed or prescribed Disulfiram (Antabuse®)
- _____ Dispensed or prescribed Naltrexone
- _____ Dispensed or prescribed Acamprosate (Campral®)

**Residential Beds**

- _____ Residential beds specifically designated for substance use treatment

### ALL SUBSTANCE USE TREATMENT SETTINGS

**Percent of Total Clients in Treatment on March 29, 2019 for use of:**

- _____% BOTH alcohol and substances other than alcohol
- _____% ONLY alcohol
- _____% ONLY substances other than alcohol
- 100% (Sum of categories above)

**Percent of Co-occurring Clients in Treatment on March 29, 2019**

- _____% Diagnosed co-occurring mental and substance use disorder

**Substance Use Treatment Admissions**

- _____ Number of substance use treatment admissions in most recent 12-month period